ArticleOncoimmunology
Oncolytic vaccines increase the response to PD-L1 blockade in immunogenic and poorly immunogenic tumors.
Article in Oncoimmunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 50 citations in OpenAlex.
- CD300ld blockade overcomes PMN-MDSC-mediated vaccine resistance in advanced tumors.Journal for immunotherapy of cancer · 2026Article
- Multifactoral immune modulation potentiates durable remission in multiple models of aggressive malignancy.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2024Article
- Novel peptide-based oncolytic vaccine for enhancement of adaptive antitumor immune response via co-engagement of innate Fcγ and Fcα receptors.Journal for immunotherapy of cancer · 2024Article
- Exploring the DNAHeliyon · 2024Article
- Tumor microenvironment-modulating oncolytic adenovirus combined with GSK-3β inhibitor enhances antitumor immune response against bladder cancer.Frontiers in immunology · 2024Article
- Development of Tumor Markers for Breast Cancer Immunotherapy.Current molecular medicine · 2024Review
- Comparison of differences in immune cells and immune microenvironment among different kinds of oncolytic virus treatments.Frontiers in immunology · 2024Review
- Bifidobacterium affects antitumor efficacy of oncolytic adenovirus in a mouse model of melanoma.iScience · 2023Article
- New Treatment Horizons in Uveal and Cutaneous Melanoma.Life (Basel, Switzerland) · 2023Review
- Oncolytic virotherapy evolved into the fourth generation as tumor immunotherapy.Journal of translational medicine · 2023Review
- Systems Biology Approaches for the Improvement of Oncolytic Virus-Based Immunotherapies.Cancers · 2023Review
- A novel cancer vaccine for melanoma based on an approved vaccine against measles, mumps, and rubella.Molecular therapy oncolytics · 2022Article
- A novel immunopeptidomic-based pipeline for the generation of personalized oncolytic cancer vaccines.eLife · 2022Article
- Immune priming using DC- and T cell-targeting gene therapy sensitizes both treated and distant B16 tumors to checkpoint inhibition.Molecular therapy oncolytics · 2022Article
- Oncolytic Adenoviral Vector-Mediated Expression of an Anti-PD-L1-scFv Improves Anti-Tumoral Efficacy in a Melanoma Mouse Model.Frontiers in oncology · 2022Article
- Peptides-Coated Oncolytic Vaccines for Cancer Personalized Medicine.Frontiers in immunology · 2022Article
- Combined vaccine-immune-checkpoint inhibition constitutes a promising strategy for treatment of dMMR tumors.Cancer immunology, immunotherapy : CII · 2021Article
- Article
- Therapeutic Cancer Vaccination with Immunopeptidomics-Discovered Antigens Confers Protective Antitumor Efficacy.Cancers · 2021Article
- Characterization of a novel OX40 ligand and CD40 ligand-expressing oncolytic adenovirus used in the PeptiCRAd cancer vaccine platform.Molecular therapy oncolytics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Activation of immune checkpoint pathways and limited T- cell infiltration result in immunological escape of tumors. Although immune checkpoint inhibitors are currently approved for several types of cancers, the response rate is often limited by the lack of tumor specific T-cells within the malignant tissue. Therefore, new combinatorial strategies are needed to enhance the clinical benefit of immune checkpoint inhibitors. We have previously developed PeptiCRAd, an oncolytic vaccine platform capable of directing the immune response toward tumor epitopes. In this study, we evaluated whether the platform could be used to increase the response rate to checkpoint inhibitors in both highly immunogenic and poorly immunogenic tumors, such as melanoma and triple negative breast cancer (TNBC). We report here that anti-PD-L1 therapy in combination with PeptiCRAd significantly reduced the growth of melanomas and increased the response rate to checkpoint inhibition. In fact, we registered a higher rate of complete responses among mice treated with the combination. This approach promoted the presence of non-exhausted antigen-specific T-cells within the tumor in comparison to anti-PD-L1 monotherapy. Furthermore, we found that targeting both MHC-I and II restricted tumor epitopes was necessary to decrease the growth of the poorly immunogenic TNBC model 4T1 and that combination with PD-L1 blockade increased the number of responders to checkpoint inhibition. Finally, the described strategy was validated in a translational
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.